The $330M Bet on Fixing a Broken Protein That Just Blew Up

Sionna's approach was to stabilize that foundation directly. The existing Vertex drugs (Trikafta and its newer sibling, vanzacaftor/tezacaftor/deutivacaftor) mostly work on other parts of the protein. They shore up the walls and doors but leave the cracked foundation largely untouched. Sionna bet that fixing NBD1 on top of Trikafta would unlock a new level of correction.

It didn't work. At least, not with SION-719.

The Pivot: Same Science, Different Horse

Sionna isn't shutting down entirely. The company is doubling down on a dual combination of SION-451 and SION-2222, two other compounds from its pipeline. The idea is that pairing two NBD1-targeting agents together (rather than layering one on top of Trikafta) might be the better path.

A Phase 2a trial for that combination is expected to launch in Q1 2027. And thanks to the layoffs, Sionna says it has enough cash to operate into the second half of 2029, giving it a reasonably long runway to prove the new strategy works.

But investors aren't exactly celebrating. Raymond James downgraded the stock from Strong Buy to Market Perform after the restructuring. The concern isn't just about one failed drug; it's about how thin the pipeline has become. Sionna went from a multi-program company to a one-bet shop overnight. If SION-451 plus SION-2222 doesn't pan out, there's no backup plan.

The Graveyard After Trikafta

Sionna's stumble highlights a broader truth about CF drug development: Trikafta set the bar so high that clearing it feels almost impossible.

Vertex's triple combo already delivers dramatic improvements for roughly 90% of CF patients. When you're trying to add benefit on top of a drug that already works this well, the incremental gains shrink. Proving statistical significance in a clinical trial becomes brutally hard because the baseline is already so good.

Sionna raised approximately $330 million in private funding before going public in February 2025, selling shares at $18 apiece and pulling in another $190.6 million from the IPO. Backers included OrbiMed, RA Capital, T. Rowe Price, and the Cystic Fibrosis Foundation itself. That's a lot of smart money that believed in the NBD1 thesis.

And Sionna isn't alone in struggling. The competitive landscape reads like a list of long shots. AbbVie is the most direct modulator competitor to Vertex, with its own corrector and potentiator combo in development. Beyond traditional modulators, companies like ReCode Therapeutics and Arcturus Therapeutics are pursuing inhaled mRNA therapies that could bypass CFTR mutations entirely. Spirovant Sciences and 4D Molecular Therapeutics are chasing gene therapy approaches. Even Moderna and Vertex have teamed up on an inhaled mRNA candidate called VX-522.

But most of these programs are still in early stages. For now, Vertex owns the CF market, and everyone else is trying to find a crack in the armor.

What This Means for Patients

For the roughly 10% of CF patients whose mutations don't respond to Trikafta, the need for new therapies is urgent and deeply personal. These patients have been watching from the sidelines as modulator therapy transformed outcomes for the majority. Every clinical failure delays their shot at the same kind of breakthrough.

Sionna's pivot keeps one path alive, but the timeline just got longer. A Q1 2027 trial start means meaningful data likely won't arrive until 2028 at the earliest. That's years of waiting for patients who don't have the luxury of patience.

The science behind NBD1 stabilization still makes theoretical sense. The foundation-fixing approach could be the key to unlocking even deeper CFTR correction. But biology has a way of humbling even the best theories, and Sionna just learned that lesson the hard way.

The company still has cash, a plausible scientific rationale, and a team (albeit a smaller one) committed to cracking the code. Whether that's enough to beat one of the hardest targets in drug development remains an open question. For Sionna, the next chapter starts with fewer people, fewer programs, and one very big bet.

Lutathera Just Got Its First Copycat. Radioligand Therapy Will Never Be the Same.

The FDA just approved the first-ever generic radioligand drug, a copycat of Novartis' blockbuster Lutathera. It's a regulatory first that could crack open pricing and competition in one of oncology's most complex (and expensive) drug categories.